mRNA-1010 Emerging Drug Insight and Market Forecast - 2032

“"mRNA-1010 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about mRNA-1010 for seasonal influenza in the seven major markets. A detailed picture of the mRNA-1010 for seasonal influenza in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the mRNA-1010 for seasonal influenza. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the mRNA-1010 market forecast analysis for seasonal influenza in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in seasonal influenza.

Drug Summary:

mRNA-1010 is Moderna's first seasonal influenza mRNA vaccine candidate to enter the clinic. The mRNA-1010 is a quadrivalent vaccine candidate that encodes for hemagglutinin glycoproteins of the four influenza strains recommended by the WHO for the prevention of influenza, including influenza A/H1N1, A/H3N2, and Influenza B/Yamagata- and B/Victoria-lineages. HA is a major influenza surface glycoprotein considered an important target to generate broad protection against influenza and is the primary target of currently available influenza vaccines.

In December, based on the positive interim results of the Phase I study of the quadrivalent flu vaccine, mRNA-1010, the company announced the successfully boosted titers against all four flu strains in older and younger adults, even at the lowest dose, with no significant safety concerns. These were important milestones toward developing an annual pan-respiratory single-dose booster vaccine adapted to the circulating strains of seasonal influenza, SARS-CoV-2, and RSV.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the mRNA-1010 description, mechanism of action, dosage and administration, research and development activities in seasonal influenza.
• Elaborated details on mRNA-1010 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the mRNA-1010 research and development activities in seasonal influenza across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around mRNA-1010.
• The report contains forecasted sales of mRNA-1010 for seasonal influenza till 2032.
• Comprehensive coverage of the late-stage emerging therapies for seasonal influenza.
• The report also features the SWOT analysis with analyst views for mRNA-1010 in seasonal influenza.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

mRNA-1010 Analytical Perspective by DelveInsight

• In-depth mRNA-1010 Market Assessment

This report provides a detailed market assessment of mRNA-1010 for seasonal influenza in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

• mRNA-1010 Clinical Assessment

The report provides the clinical trials information of mRNA-1010 for seasonal influenza covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for seasonal influenza is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence mRNA-1010 dominance.
• Other emerging products for seasonal influenza are expected to give tough market competition to mRNA-1010 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of mRNA-1010 in seasonal influenza.
• Our in-depth analysis of the forecasted sales data of mRNA-1010 from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the mRNA-1010 in seasonal influenza.

Key Questions

• What is the product type, route of administration and mechanism of action of mRNA-1010?
• What is the clinical trial status of the study related to mRNA-1010 in seasonal influenza and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the mRNA-1010 development?
• What are the key designations that have been granted to mRNA-1010 for seasonal influenza?
• What is the forecasted market scenario of mRNA-1010 for seasonal influenza?
• What are the forecasted sales of mRNA-1010 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to mRNA-1010 for seasonal influenza?
• Which are the late-stage emerging therapies under development for the treatment of seasonal influenza?